Welcome to our dedicated page for LB Pharmaceuticals SEC filings (Ticker: LBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The LB Pharmaceuticals Inc (LBRX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission, alongside AI-assisted summaries to help interpret the information. As a clinical-stage biopharmaceutical company focused on schizophrenia, bipolar depression, and other neuropsychiatric diseases, LB Pharmaceuticals uses SEC filings to report on its financial condition, clinical development plans, corporate governance, and material agreements.
Core documents for LBRX include its registration statement on Form S-1/A, which describes the company’s business, risk factors, and the role of its lead product candidate, LB-102. This filing outlines LB-102’s status as a Phase 3–ready oral, small-molecule drug and a methylated derivative of amisulpride, and explains the company’s focus on neuropsychiatric indications such as acute schizophrenia and bipolar depression. Periodic reports and earnings-related Form 8-K filings provide condensed balance sheets, statements of operations, and narrative updates on research and development and general and administrative expenses.
Other current reports on Form 8-K document material corporate events, including lease amendments for additional office space, appointments of senior executives, and press releases announcing quarterly financial results. These filings also confirm that LB Pharmaceuticals’ common stock is listed on The Nasdaq Stock Market LLC under the ticker LBRX and that the company is incorporated in Delaware.
On Stock Titan, users can review these filings in chronological order and use AI-powered summaries to quickly understand key points from lengthy documents, such as the implications of clinical trial disclosures, changes in operating expenses, or the significance of material agreements. Access to insider transaction reports on Form 4, annual reports on Form 10-K, and quarterly reports on Form 10-Q, when filed, can further support analysis of LBRX’s progress as a clinical-stage biopharmaceutical issuer.
Deep Track Capital and affiliates updated their ownership filing for LB Pharmaceuticals Inc. after participating in a private placement. Following the transaction, Deep Track Capital, LP and David Kroin report beneficial ownership of 3,352,804 shares of common stock, representing 11.7% of the company.
The issuer sold 3,306,571 common shares and pre-funded warrants to purchase up to 1,417,107 additional shares in the private placement. Deep Track Biotechnology Master Fund, Ltd holds 2,686,138 shares, or 9.4% of the class, and Deep Track Special Opportunities Fund, LP holds 666,666 shares, or 2.3%. The pre-funded warrants have a $0.0001 exercise price and are subject to a 9.99% beneficial ownership cap, so the reporting persons currently disclaim beneficial ownership of the underlying warrant shares. LB Pharmaceuticals agreed to register the resale of the purchased shares and warrant shares on a Form S-1 and to keep that registration effective under specified conditions.
LB Pharmaceuticals Inc. reported insider purchases of pre-funded warrants by Deep Track-affiliated funds. On February 6, 2026, Deep Track Biotechnology Master Fund, Ltd. acquired 378,444 pre-funded warrants, and Deep Track Special Opportunities Fund, LP acquired 93,925 pre-funded warrants, each at
The pre-funded warrants are exercisable immediately at an exercise price of
LB Pharmaceuticals Inc entered into a private placement financing, agreeing to sell 3,306,571 common shares and pre-funded warrants for up to 1,417,107 additional shares at prices around $21.17 per share, for estimated gross proceeds of about $100 million.
The company plans to use the net proceeds mainly to fund a Phase 2 trial of LB-102 as an adjunctive treatment for major depressive disorder, as well as for working capital and general corporate purposes. The multi-center, six-week trial is expected to enroll about 380 patients across roughly 50 sites in the U.S. and Europe.
LB Pharmaceuticals Inc. disclosed that BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in the company’s common stock. As of December 31, 2025, BlackRock reported beneficial ownership of 1,277,776 shares, representing 5.1% of LB Pharmaceuticals’ outstanding common stock.
BlackRock reported sole power to vote 1,262,836 shares and sole power to dispose of 1,277,776 shares, with no shared voting or dispositive power. The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of LB Pharmaceuticals.
BlackRock Portfolio Management LLC filed an amended Schedule 13G reporting a passive ownership stake in LB Pharmaceuticals Inc. common stock. The firm reports beneficial ownership of 961,158 shares, representing 3.8 % of the outstanding common stock. It has sole power to vote 863,342 shares and sole power to dispose of 961,158 shares, with no shared voting or dispositive power. The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of LB Pharmaceuticals. Various persons have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.
JPMorgan Chase & Co. has filed a Schedule 13G reporting a passive ownership stake in LB Pharmaceuticals Inc. common stock. The firm reports beneficial ownership of 1,611,482 shares, representing 6.3% of the company’s outstanding common stock as of the event date.
JPMorgan has sole voting power over 1,471,295 shares and sole dispositive power over 1,611,482 shares, with no shared voting or dispositive power. The filing is certified as being made in the ordinary course of business and states that the securities are not held for the purpose of changing or influencing control of LB Pharmaceuticals.
LB Pharmaceuticals reported that its chief commercial officer received an employee stock option grant covering 195,000 shares of common stock. The option, dated 12/10/2025, has an exercise price of $21.36 per share and expires on 12/09/2035.
One fourth of the shares vest on 11/10/2026, with the remaining shares vesting in 36 equal monthly installments on the last calendar day of each month starting 12/31/2026, subject to the officer’s continuous service. Following this grant, the officer beneficially owns 195,000 stock options, held directly.
LB Pharmaceuticals Inc. (LBRX)no securities beneficially owned in LB Pharmaceuticals. This establishes that the executive currently holds no direct or indirect ownership in the company’s securities under the relevant reporting rules.
LB Pharmaceuticals (LBRX) amended its headquarters lease to add 4,634 rentable square feet on the 10th floor at One Penn Plaza, New York. The underlying lease term remains scheduled to expire on March 31, 2032.
The landlord shall endeavor to deliver the Expansion Premises on or prior to July 1, 2026. From the Expansion Premises Commencement Date, fixed rent for the added space will be $430,962 per year for the first three years, increasing to $477,302 per year on the third anniversary. The parties agreed to a fixed rent abatement for the first 150 days after commencement, as set forth in the amendment.
LB Pharmaceuticals (LBRX) appointed Kaya Pai Panandiker as Chief Commercial Officer, effective November 10, 2025, and announced the move via a press release. The company also plans to grant her an equity award as an inducement to join, made outside of—but subject to—the 2025 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). A copy of the press release is filed as Exhibit 99.1.
FAQ
What is the current stock price of LB Pharmaceuticals (LBRX)?
What is the market cap of LB Pharmaceuticals (LBRX)?
